1-4 of 4
Angela J. Howes
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Safety and Efficacy of Cusatuzumab in Combination with Venetoclax and Azacitidine (CVA) in Patients with Previously Untreated Acute Myeloid Leukemia (AML) Who Are Not Eligible for Intensive Chemotherapy; An Open-Label, Multicenter, Phase 1b Study

Gail J. Roboz, Thomas Pabst, Ahmed Aribi, Joseph M. Brandwein, Hartmut Döhner, Walter Fiedler, Domenica Gandini, Michelle Geddes, Jing-Zhou Hou, Angela J. Howes, Anna Hultberg, Eric Huselton, Julie Jacobs, Colleen Kane, Ewa Lech-Marańda, Marieke Louwers, Kerri Nottage, Uwe Platzbecker, Raajit Rampal, Mariya Salman, Priya Shah, Don Stevens, Monic Stuart, Marion Subklewe, Anne Sumbul, Eunice S. Wang, Agnieszka Wierzbowska, Bin Yao, Karen Yee, Hagop Kantarjian, Gautam Borthakur
Journal: Blood
Blood (2021) 138 (Supplement 1): 369.
https://doi.org/10.1182/blood-2021-150371
Published: 2021
Journal Articles

Risk Model for Overall Survival for Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia: Validated for Patients on Ibrutinib, Idelalisib, Venetoclax, or Chemoimmunotherapy

Jacob D. Soumerai, MD, Ai Ni, PhD, Mohamed Darif, PhD, Anil Londhe, PhD, Guan Xing, PhD, Yong Mun, PhD, Neil E. Kay, MD, Tait D. Shanafelt, MD, Kari G. Chaffee, MS, Richard R. Furman, MD, Peter Hillmen, MB ChB, PhD FRCP, FRCPath, Jeff Sharman, MD, John F. Seymour, MBBS, PhD, Asher A. Chanan-Khan, MD, John C. Byrd, MD, Jeffrey A. Jones, MD MPH, Lucille A. Ferrante, MD, Lyndah K. Dreiling, MD, Mehrdad Mobasher, MD MPH, Thomas Stark, MD PhD, Vijay Reddy, MD PhD, Angela J. Howes, BSc, PhD, Danelle James, MD MAS, Pankaj Bhargava, MD, Andrew D. Zelenetz, MD PhD
Journal: Blood
Blood (2018) 132 (Supplement 1): 4394.
https://doi.org/10.1182/blood-2018-99-112989
Published: 2018
Journal Articles

A randomized phase 3 study of tipifarnib compared with best supportive care, including hydroxyurea, in the treatment of newly diagnosed acute myeloid leukemia in patients 70 years or older

Clinical Trials & Observations
Jean-Luc Harousseau, Giovanni Martinelli, Wieslaw W. Jedrzejczak, Joseph M. Brandwein, Dominique Bordessoule, Tamas Masszi, Gert J. Ossenkoppele, Julia A. Alexeeva, Gernot Beutel, Johan Maertens, Maria-Belen Vidriales, Hervé Dombret, Xavier Thomas, Alan K. Burnett, Tadeusz Robak, Nuriet K. Khuageva, Anatoly K. Golenkov, Elena Tothova, Lars Mollgard, Youn C. Park, Annick Bessems, Peter De Porre, Angela J. Howes, for the FIGHT-AML-301 Investigators
Journal: Blood
Blood (2009) 114 (6): 1166–1173.
https://doi.org/10.1182/blood-2009-01-198093
Published: 2009
Journal Articles

A Randomized Phase 3 Study of Tipifarnib Compared to Best Supportive Care (Including Hydroxyurea) in the Treatment of Newly Diagnosed Acute Myeloid Leukemia (AML) in Patients 70 Years or Older.

Jean-Luc Harousseau, Giovanni Martinelli, Wieslaw W. Jedrzejczak, Joseph Brandwein, Dominique Bourdessoule, Tamas Masszi, Gert Ossenkoppele, Julia A. Alexeeva, Gernot Beutel, Youn C. Park, Peter De Porre, Angela J. Howes
Journal: Blood
Blood (2007) 110 (11): 439.
https://doi.org/10.1182/blood.V110.11.439.439
Published: 2007